China Blood Products Industry Report, 2009
  • Oct/2009
  • Hard Copy
  • USD $1,100
  • Pages:42
  • Single User License
    (PDF Unprintable)       
  • USD $1,200
  • Code: ZN006
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,300

The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China’s blood products has soared up and corporate profitability also has increased significantly.

China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.

China’s Plasma Collection, 2001-2010E
Source: ResearchInChina

The report makes an in-depth analysis of the status quo of China’s blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China’s seven key blood product companies, such as Hualan Biological Engineering Inc.

As a key company of blood products R&D and production in China, the revenue of Hualan Biological Engineering Inc achieved RMB475 million in 2008, up 35.32% year-on-year; and the total profit was RMB218 million, a 69.73% YoY rise. Moreover, the current and newly-built plasma collection stations primarily distribute in Guizhou, Guangxi and Chongqing. Up to 2008, it had owned 11 plasma collection stations, and three under construction. It has eased the short supply of plasma via building new plasma collection stations.

Hualan Biological Engineering has taken the lead in blood products field in China, in the meantime, it has accessed into vaccine sector actively. It was the first to obtain Influenza A strain on Jun 8, 2009, and it entered the clinical trials on July 22. The monthly output capacity of Influenza A vaccine can reach 7.5 million units, and it would carry the reserves of 4 million units before Sep 15. Besides, it had produced 13 million units of Influenza A vaccine before Oct 1. As is estimated, it can supply 35-40 million units of Influenza A vaccine by the end of 2009.

Prime Operating Revenue of Hualan Biological Engineering Inc, 2007-2011E
Source: ResearchInChina

1 China’s Blood Products Industry
1.1 Market  
1.1.1 Profile
1.1.2 Industry Characteristics 
1.2 Competitive Patterns
1.3 Existing Problems
1.4 Development Trend 
2. China’s Plasma Market
2.1 Plasma Collection Station 
2.2 Plasma Volume 
2.3 Plasma Price
2.4 Difficulties in Industry Development 
2.5 Development Trend 

3. Global Blood Products Industry
3.1 Development Courses
3.2 Status Quo 
3.3 Comparison between China and International Blood Products Industry Development 
4. Key Blood Products
4.1 HSA
4.2 IVIG
4.3 HBIG
4.4 Rabies Immunoglobulin
4.5 Tetanus Immunoglobulin  
4.6 Coagulation Factor FVIII 

5. Key Manufacturers in China 
5.1 Overall Analysis
5.2 Hualan Biological Engineering Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Development Trend 
5.3 Shanghai RAAS Blood Products Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Development Trend
5.4 CNBG Shanghai Institute of Biological Products
5.4.1 Profile
5.4.2 Operation
5.5 Beijing Tiantan Biological Products Co., Ltd 
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Trend
5.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
5.6.1 Profile
5.6.2 Operation
5.7 Guiyang Qianfeng Biological Product Liability Co., Ltd.

6. Investment  
6.1 Opportunities 
6.2 Risks
6.3 Suggestions   
Varieties, Applications and Manufacturers of China’s Main Blood Products 
Management Modes of Plasma Collection Station before System-Reform 
Blood Product Industry Chain after System-Reform 
State’s Laws & Regulations on Blood Products Industry
Plasma Volume Trend of China’s Blood Products, 2003-2011
China’s Plasma Collection Volume Trend, 2001-2010 
Comparison between China’s and International Blood Product Market Structure, 2008 
China’s HSA Output, 2005-2008 
China’s HSA Prices, 2003-2010 
China’s IVIG Output, 2003-2008 
China’s IVIG Prices, 2003-2010 
Concentration Trend of Companies in the Future
Plasma Collection Capability of Hualan Biological Engineering’s Current and Would-be Plasma Collection Stations  
Revenue/Cost Structure of Hualan Biological Engineering, 2008 
Main Business Revenues of Hualan Biological Engineering, 2007-2011 
Profitability of Hualan Biological Engineering, 2008-2011 
The Number of Hualan Biological Engineering’s Plasma Collection Stations, 2008 
China’s Flu Vaccine Market Share, 2008 
Shanghai RAAS Revenue/Profit Ratio by Business, 2008 
Shanghai RAAS Revenue/Gross Profit Structure, 2008 
Shanghai RAAS Product Price Trend, 2005-2011 
Shanghai RAAS Projects Invested by Fund-Raising, 2008 
Output Capacity Comparison of Shanghai RAAS Fund-Raising Investment Projects before and after Completion, 2008  
The List of SIBP Products
Revenue Trend of Beijing Tiantan Biological, 2008-2011 
Beijing Tiantan Biological Revenue Change before and after Acquisition of Chengdu Rongsheng 
Products List of Guiyang Qianfeng
China’s HSA Provisional Maximum Retail Price, 2008

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号